|
FDA Approves Reformulated Ranitidine - Nitrosamine Impurities - NDMA
|
|
3
|
407
|
November 27, 2025
|
|
Nitrocellulose-Based Packaging Inks and Nitrosamine Risk
|
|
0
|
286
|
October 28, 2025
|
|
DMF in API, specification limit in formulation
|
|
5
|
849
|
August 26, 2024
|
|
AI Limit for Nitroso Nebivolol
|
|
11
|
2891
|
April 3, 2024
|
|
Entidades regulatorias y su postura en el análisis de nitrosaminas en estudios de estabilidad de preparados farmacéuticos
|
|
0
|
252
|
February 28, 2024
|
|
Patient In-Use Stability Testing of FDA-Approved Metformin Combination Products for N-Nitrosamine Impurity
|
|
6
|
661
|
January 31, 2024
|
|
Variation requirements
|
|
2
|
464
|
October 2, 2023
|
|
Formation of N-nitroso Fluconazole and Related Triazole-Imidazole APIs
|
|
4
|
1469
|
June 9, 2023
|
|
Prediction of Nitrosamine formation from Excipients
|
|
19
|
1836
|
February 8, 2023
|
|
Stress condition in COC impurity
|
|
6
|
775
|
May 24, 2022
|
|
New webinar & Live Q&A May 24th by Naiffer Romero! Nitrosamine exchange – a USP’s knowledge community for all-things nitrosamine
|
|
0
|
407
|
April 22, 2022
|